Powered by Mode Mobile
MarketMunchiesπŸ”
LIVE
EUR/USD1.1759●▲ +0.32%Bitcoin73,345●▲ +3.67%Ethereum2,257.9●▲ +3.01%S&P 500742.71●▲ +0.20%NASDAQ714.51●▲ +0.19%Gold3,238.4●▲ +1.82%Oil (WTI)61.42●▼ βˆ’2.15%GBP/USD1.3124●▲ +0.18%EUR/USD1.1759●▲ +0.32%Bitcoin73,345●▲ +3.67%Ethereum2,257.9●▲ +3.01%S&P 500742.71●▲ +0.20%NASDAQ714.51●▲ +0.19%Gold3,238.4●▲ +1.82%Oil (WTI)61.42●▼ βˆ’2.15%GBP/USD1.3124●▲ +0.18%
Analysis

Marijuana Is Now Schedule III. Cannabis Stocks Exploded. But Is This a Real Inflection Point?

After decades of false starts, bureaucratic delays, and enough political theater to fill a Senate subcommittee, the federal government finally did it. On Thursday, Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana from Schedule…

Shane MurphyΒ·Apr 24, 2026Β·7 min read
Apr 24 news2

After decades of false starts, bureaucratic delays, and enough political theater to fill a Senate subcommittee, the federal government finally did it.

On Thursday, Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. Cannabis stocks surged. Tilray Brands jumped 14%, Canopy Growth climbed 21%, and Curaleaf surged 26%. The AdvisorShares US Cannabis ETF (MSOS) gained nearly 20% in a single session.

The question investors should be asking the morning after is the same one they should always ask after a historic rally: does the underlying reality justify the price, or are they buying the headline?

What Actually Changed β€” and Why It Happened Now

Β 

Before getting into what the market is pricing in, it is worth being precise about what Thursday's order actually does β€” and what it does not.

The reclassification did not arrive out of nowhere. In December 2025, President Trump signed an executive order directing the DOJ to complete the rescheduling process "in the most expeditious manner possible." When progress stalled, Trump complained publicly that agencies were "slow-walking" him. Thursday's order, signed by Blanche using a specific legal authority that bypassed the stalled DEA rulemaking process entirely, was the culmination of that top-down political directive. This was not a spontaneous bureaucratic decision. It was a presidential mandate that finally got executed.

The order itself moves two specific categories of marijuana to Schedule III: FDA-approved drug products containing marijuana, and products regulated under a qualifying state medical marijuana license. Everything else β€” including recreational cannabis in adult-use states β€” remains Schedule I. This is not federal legalization. It is not even close.

What the reclassification does deliver is meaningful in a narrower sense. The most significant impact is the removal of IRS Code Section 280E, one of the most punishing features of federal marijuana policy for legal operators. Under 280E, cannabis companies could not deduct ordinary business expenses β€” rent, payroll, utilities β€” from their federal taxes because they were classified as trafficking in a controlled substance. The result for many operators was an effective federal tax rate of 60% to 70%, applied to gross profit rather than net income. That restriction is now lifted for covered medical marijuana operators, cutting their effective tax rate down to the standard 21% corporate rate. The reclassification also lowers barriers for clinical research and, as Ricardo Baca, founder of public affairs firm Grasslands, put it, represents "the single-biggest U.S. drug policy shift of our lifetimes." That is not nothing.

The Part the Stock Rally Is Glossing Over

Β 

Here is where investors need to take a step back from the green candles.

Canada legalized cannabis fully in 2018. Not rescheduled it β€” actually legalized it, nationwide, for recreational use. And what followed was not a golden era for cannabis companies. It was oversupply, price compression, margin collapse, and a wave of insolvencies. Licensed producers expanded frantically into a market that was not ready to absorb them. Prices fell from more than $7 per gram to around $3 per gram in some markets within a year of legalization. Companies that had been celebrated as the vanguard of a new industry spent the next five years closing facilities, laying off workers, and writing down assets.

Canada's experience is the most instructive case study the U.S. cannabis industry has available to it. And the lesson it teaches is that policy change does not automatically create a functioning, profitable business. Regulatory friction and tax burden are real problems β€” removing them helps β€” but they are not the only problems. Oversupply, price compression, and a fragmented state-by-state market structure are just as real, and Thursday's order does not touch any of them.

Recreational cannabis in every adult-use state still operates under its own rules. Interstate commerce remains illegal. A California dispensary cannot source product from Colorado or ship to New York. The illicit market, which undercuts legal prices by margins that no tax break can fully close, still exists. The structural economics of the U.S. cannabis industry are complicated. Lower taxes make them less complicated. They do not make them simple.

The Investor Reality

Β 

For investors holding cannabis equities, Thursday's announcement is a genuine positive. Removing 280E directly improves the cash flow math for every covered medical marijuana operator. For multi-state operators that have been paying taxes on gross income rather than net income, the difference is potentially material β€” though investors should temper expectations on timing. The IRS has not yet clarified when exactly 280E relief takes effect: at the time of Thursday's order, retroactively to the start of the tax year, or at the beginning of the following tax year. Depending on that determination, some operators may not see the actual cash flow benefit until 2027. The policy win is real; whether it shows up in the next set of quarterly results is a separate question.

The stocks that are best positioned are operators with strong balance sheets, diversified state footprints, and a meaningful medical revenue mix. But here is where the market structure creates a crucial complication that most coverage of Thursday's rally glossed over entirely.

The Canadian companies β€” Tilray, Canopy Growth, Aurora Cannabis β€” trade on major U.S. exchanges like the NYSE and Nasdaq because they are incorporated in Canada and do not directly touch the U.S. cannabis plant. That technicality allows them to list on exchanges that would otherwise refuse them. The irony is that these companies have limited direct exposure to U.S. multi-state operations, which are where the 280E relief actually bites hardest.

The genuine U.S. multi-state operators β€” Green Thumb Industries, Curaleaf, Trulieve β€” are the companies with the most to gain from Thursday's order. But they are forced to trade on over-the-counter markets because major U.S. exchanges will not list companies that operate in violation of federal law. That keeps institutional capital almost entirely off the table. Mutual funds, pension funds, and most ETFs cannot hold OTC securities. Until banking reform β€” specifically legislation like the SAFER Banking Act β€” clears that barrier, the companies with the greatest fundamental upside from rescheduling remain structurally inaccessible to the investors who could most meaningfully re-rate them.

That gap between who benefited most in the Thursday rally and who stands to benefit most from the underlying policy change is the central tension investors need to understand before chasing this trade.

What to Watch

Β 

The June 29 administrative hearing is the next significant milestone, addressing broader reclassification beyond the medical-only categories covered by Thursday's order. Any expansion to include adult-use cannabis would be a materially larger event.

Banking reform remains the other major unlock. As MJBizDaily noted, sustained equity appreciation in cannabis requires not just 280E relief but genuine institutional ownership β€” and that requires banking access that rescheduling alone does not provide.

Thursday was a real development. It is the most significant shift in federal cannabis policy in decades, and it will have measurable positive effects on the finances of legal operators. But it is also the kind of news that has a history of generating stock moves that get partially reversed once the market finishes digesting what actually changed versus what it initially assumed.

The rally celebrated a policy shift. The fundamentals β€” oversupply, price compression, fragmented state markets, OTC-trapped U.S. operators, and a banking system that still won't touch the sector β€” are still there the morning after.

Sources

Β 

Market Munchies and Mode Mobile communications are for informational purposes only, and are not a recommendation, solicitation, or research report relating to any investment strategy, security, or digital asset. All investments involve risk including the loss of principal and past performance does not guarantee future results.

Any information contained in this commentary does not purport to be a complete description of the securities, markets, or developments referred to in this material. The information has been obtained from sources considered to be reliable, but we do not guarantee that the foregoing material is accurate or complete. There is no guarantee that any statements or opinions provided herein will prove to be correct.